Arterial Remodeling Technologies ("ART") to Disclose New Data About its Bioresorbable Stent at the 9th Annual 'EBR Symposium 2010', May 6th
“We are the leading innovator in the field of next-generation technology for fully resorbable coronary stents that promote natural remodeling of an injured artery after angioplasty.”
Machiel van der Leest, CEO
PARIS--(BUSINESS WIRE)--May 3, 2010 - Arterial Remodeling Technologies (“ART”) announced today that it will disclose new data related to its bioresorbable stent platform—additional data that further validates the Company's innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent. The data will be disclosed by CEO Machiel van der Leest on Thursday, May 6, 2010, at the 9th annual ˜EBR (Endocardiac Biomechanics Research) Symposium 2010' in Marseille, France.
Previous validating data regarding ART's next-generation bioresorbable stent approach has been published in the January 2010 special supplement of EuroIntervention, a peer-reviewed journal. The paper was authored by Antoine Lafont, M.D., Ph.D., Head, Interventional Cardiology Department, Georges Pompidou Hospital (Paris); Past Chairman, Interventional Cardiology Group, European Society of Cardiology (ESC).
“Since the mechanical scaffold of a bioresorbable stent is only required over a limited healing period to avoid elastic recoil of the artery, an alternative non-permanent treatment with a bioresorbable stent is commonly regarded as the next-generation therapeutic device,” said Machiel van der Leest, CEO, who previously was a co-founder and Chief Technology Officer of Minvasys. During his career he has developed and successfully introduced 15 Class III medical devices, which required pre-market approval and a scientific review to ensure safety and effectiveness.
“ARTs next-generation bioresorbable coronary stent is designed to provide a transient effective scaffold that will dismantle and loose its primary mechanical scaffolding function after three months—the period universally recognized by experts as necessary to allow the healing process to stabilize the artery following the trauma generated by an angioplasty. The complete resorption of all the monomers (basic elements that form polymers) is estimated to occur within 18 months,” van der Leest said.
“ART's stent is designed to have several competitive benefits over existing bioresorbable stents in development: (1) faster and smoother resorption; (2) non-crystalline polymer; (3) superior preserved material, without harmful by-products; (4) better, homogeneous stress diffusion; and (5) crack- and crazing-free expansion,” explained van der Leest. “The ART device is designed to be delivered by conventional stenting techniques, is balloon-expandable and meets the market standard of 6-French compatibility,” added van der Leest.
ART's novel biopolymers have been developed in conjunction with one of the world's leading authorities in polymer chemistry, Professor Michel Vert, who is Former Director of the Research Center for Artificial Biopolymers at France's National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS).
Arterial Remodeling Technologies (“ART”) is developing bioresorbable coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The Company's technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, CNRS (Centre National de Recherche Scientifique), Montpellier, France; and, Descartes University, Paris.
Contact: Ronald Trahan Associates Inc.
Ronald Trahan, APR, 508-359-4005, x108
Posted: May 2010